Karnataka Government Launches Kusuma Sanjeevini Programme for Hemophilia Patients

The Government of Karnataka (GoK) has made a first step towards preventive healthcare by providing better treatment for hemophilia, a rare genetic blood disorder, to those who are afflicted. This includes improving the dissemination of the prophylaxis treatment and specialised 108 ambulances to the hemophilia patients in Karnataka, provision of which would ensure adequate medical intervention, and help reduce the lifelong disability caused by uncontrolled bleeding attacks.

Strengthening Preventive Care for Hemophilia

Hemophilia is a very rare inherited bleeding disorder that is characterised by spontaneous and prolonged bleeding, especially into the joints, leading to difficulties in mobility and a risk of permanent joint damage if treatment is delayed. The Karnataka government, under the Kusuma Sanjeevini programme, is shifting the paradigm from "reactive treatment" to "preventive treatment" by encouraging the use of prophylactic treatment.

Dr. Rajwinder (Rajji) Mehdwan, the Medical Director & CEO of Roche Pharma India, spells out the significance of the initiative for the survival and life story of people who have hemophilia in Karnataka. Patients will receive flexible subcutaneous doses as prophylaxis and will find the treatment easier, and it is expected that this will ease the burden on families and the health system,” he said.

According to Precedence Research, the hemophilia market size was calculated at USD 12.50 billion in 2025 and is predicted to increase from USD 13.31 billion in 2026 to approximately USD 23.46 billion by 2035, expanding at a CAGR of 6.50% from 2026 to 2035, due to growing awareness, rising diagnosis rates, and rising R&D investment in hemophilia prevention and treatment.

Industry Impact and Future Outlook

Karnataka is taking pioneering steps towards addressing the inequity and healthcare access issues for rare diseases by combining prognosis and emergency treatment. These are seen as solutions to stimulate the use of new hemophilia therapies and to support the management of chronic diseases and long-term hemophilia patient care.